Core C Clinical Trials Core: The function of Core C is to facilitate the translation of laboratory findings into the necessary clinical and correlative studies. This Clinical Trials Core provides the support and resources for activation, conduct and completion of the clinical trials or clinically-related aspects of each of the projects. This Core will provide the infrastructure so that concepts emanating from the projects can be evaluated for translational suitability, formulated into appropriate clinical protocols that will be carried out with the appropriate regulatory oversight, safety and collection of clinical data. This core is a necessary and vital component of the SARC Sarcoma SPORE and will streamline and standardize interaction with the clinical trial infrastructure of forty sarcoma clinical trials centers across the United States. The success of SARC is significantly based upon an outstanding record of accomplishment of designing, conducting and analyzing clinical trials in patients with sarcoma. SARC Clinical Trials Core leadership under the direction of Laurence Baker is experienced in facilitating multi-center research.

Public Health Relevance

Currently there are limited programs that have the capabilities to provide the infrastructure for collaboration on clinical trial research for sarcoma. Because sarcoma is a relatively uncommon disease and that it occurs across the human like span, this clinical trial Core will provide the infrastructure to facilitate the conduct of clinical research to identify new beneficial treatment options for patients with sarcoma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ann Arbor
United States
Zip Code
Feng, Yong; Sassi, Slim; Shen, Jacson K et al. (2015) Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. J Orthop Res 33:199-207
Monument, Michael J; Johnson, Kirsten M; McIlvaine, Elizabeth et al. (2014) Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group. PLoS One 9:e104378
Choy, Edwin; Butrynski, James E; Harmon, David C et al. (2014) Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 14:813
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10
Sankar, Savita; Theisen, Emily R; Bearss, Jared et al. (2014) Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res 20:4584-97
Zhang, Pingyu; Garnett, Jeannine; Creighton, Chad J et al. (2014) EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J Pathol 232:308-18
Sioletic, Stefano; Czaplinski, Jeffrey; Hu, Lan et al. (2014) c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol 234:190-202
Chen, Eleanor Y; DeRan, Michael T; Ignatius, Myron S et al. (2014) Glycogen synthase kinase 3 inhibitors induce the canonical WNT/?-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci U S A 111:5349-54
Krook, Melanie A; Nicholls, Lauren A; Scannell, Christopher A et al. (2014) Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma. Mol Cancer Res 12:953-64
Jia, Bin; Choy, Edwin; Cote, Gregory et al. (2014) Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. Cancer Lett 342:104-12

Showing the most recent 10 out of 13 publications